Brigatinib is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).
🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
It inhibits autophosphorylation of ALK and ALK-mediated phosphorylation of downstream signaling proteins such as STAT3, AKT, ERK1/2, and S6 in vitro and in vivo assays.
Demonstrated dose-dependent inhibition of EML4-ALK-positive NSCLC xenograft growth in mice.
Primarily metabolized by CYP2C8 and CYP3A4 in vitro. The major metabolite, AP26123, has lower potency against ALK compared to Brigatinib.
Excreted mainly through feces (65%) and urine (25%).
The recommended dosing regimen for Brigatinib is as follows:
Note: Patients should follow the dosage instructions as directed by the registered physician.
Avoid strong CYP3A inhibitors; if unavoidable, reduce the Biganib dose by approximately 50%. Strong CYP3A inducers should be avoided as they may decrease Brigatinib efficacy.
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.